Webinar: Using ALS Patient-Derived Motor Neurons to Study TDP-43 Mislocalization by InsideScientific

How would you rate today’s webinar on a scale from 1-5 stars?

1

Not so great
2

Fair
3

Good
4

Great
5

Amazing

Using ALS Patient-Derived Motor Neurons to Study TDP-43 Mislocalization

About

In this webinar, Vera Evanson, PhD will present how iPSC-derived ALS models reproduce hallmark disease phenotypes and their use in evaluating drug responses.

Amyotrophic Lateral Sclerosis (ALS) remains one of the most challenging neurodegenerative diseases to model and treat. Dr. Evanson will discuss how iPSC-derived ALS models reproduce TDP-43 mislocalization and how these models can be leveraged to evaluate drug responses and TDP-43 dynamics. Join to learn how Ricoh Biosciences' transcription factor-based differentiation platform enables rapid, reproducible generation of motor neurons and how these physiologically relevant models can accelerate your drug discovery, target validation, and phenotypic screening efforts in ALS research.

Key Topics:

Overview of Ricoh Biosciences' iPSC technology

How can patient-specific iPSC-derived motor neurons be used to model ALS?

What is TDP-43 and how is it implicated in ALS?

Evaluating drug efficacy using TDP-43 mislocalization in ALS models

Presenter

Vera Evanson, PhD

Lead Scientist, Research & Development, Ricoh Biosciences

Dr. Vera-Marie Evanson is an R&D Lead Scientist at Ricoh Biosciences and a lead scientist on ALS assay development, working with partners to refine our disease-modeling platform for their research needs. She specializes in assay design, high-content imaging, and image analysis, trained at Radboud University and Johns Hopkins.

First Name*

Last Name*

Email Address*

Country / Region*

Job Title*

Organization / Company*

Have a question for Vera? Ask it here:

utm_bmcr_source